What is Gyre Therapeutics, Inc.'s finance receivables (current)?

Gyre Therapeutics, Inc. (GYRE) reported finance receivables (current) of $3.82M in Q1 2026.

How has Gyre Therapeutics, Inc.'s finance receivables (current) changed year-over-year?

Gyre Therapeutics, Inc.'s finance receivables (current) increased by 78.5% year-over-year, from $2.14M to $3.82M.

What is the long-term trend for Gyre Therapeutics, Inc.'s finance receivables (current)?

Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s finance receivables (current) has grown at a 280.7% compound annual growth rate (CAGR), from $389K to $5.64M.

Gyre Therapeutics, Inc. GYRE Finance Receivables (Current)

Finance Receivables (Current) at other companies

Royalty PharmaRPRX

——

Other financials

Income statement

See full

Revenue$22.5M+2.1%

Gross profit$21.3M+0.6%

Operating income-$9.4M-512%

Net income-$8.7M-422%

EPS (diluted)-$0.10—

Balance sheet

See full

Cash & equivalents$37.5M+149%

Total debt$823.0K-48.1%

Total equity$101.3M+48.7%

Total assets$162.0M+24.8%

Cash flow

See full

Operating cash flow$3.2M+2,565%

CapEx$178.0K+45.9%

Free cash flow$3.0M+1,296%

Valuation

See full

Market cap$694.58M-4.7%

Enterprise value$657.9M-8.0%

P/S5.9×-1.3×

Profitability

See full

Gross margin95.1%-1.1pp

Operating margin-0.1%-10.4pp

Net margin6.3%+3.3pp

FCF margin2.6%—

Returns & leverage

See full

Return on equity8.2%+4.2pp

Debt / equity0×0.0×

Current ratio4.6×+1.0×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NotesAndLoansReceivableNetCurrent.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s finance receivables (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s finance receivables (current)?: Gyre Therapeutics, Inc. (GYRE) reported finance receivables (current) of $3.82M in Q1 2026.
How has Gyre Therapeutics, Inc.'s finance receivables (current) changed year-over-year?: Gyre Therapeutics, Inc.'s finance receivables (current) increased by 78.5% year-over-year, from $2.14M to $3.82M.
What is the long-term trend for Gyre Therapeutics, Inc.'s finance receivables (current)?: Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s finance receivables (current) has grown at a 280.7% compound annual growth rate (CAGR), from $389K to $5.64M.